September 2022

AbbVie announced that the FDA approved atogepant (QULIPTA) for the prevention of episodic migraines in adults.
Read More

Patients with adult-onset epilepsy who took enzyme-inducing antiseizure medications had a higher hazard of incident cardiovascular disease.
Read More

A nonresponse to esketamine nasal spray plus oral antidepressants in the first week of treatment does not predict failure of response at 4 weeks.
Read More

A national strategy of early initiation of highly effective disease-modifying therapy was associated with improved outcomes in patients with relapsing-remitting multiple sclerosis compared with an escalation strategy, according to a recent study.
Read More

On March 19, 2021, Janssen Pharmaceutical Companies announced that the US Food and Drug Administration approved ponesimod for the treatment of relapsing multiple sclerosis in adults. The approval indications include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Read More

Subscribe to Value-Based Care in Neurology

Stay up to date with the latest news in neurology by subscribing to receive the free VBCN e‑Newsletter.